PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Status:
Not yet recruiting
Trial end date:
2028-04-30
Target enrollment:
Participant gender:
Summary
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of
the total number of cardiovascular, kidney, and death events among three alternative
treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic
cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we
will randomly assign 9,000 patients with established T2D and ASCVD or high-risk for ASCVD in
a 1:1:1 allocation to SGLT2i, GLP-1RA, or the combination. Participants will be followed for
the occurrence of the trial primary endpoint of the total (first and recurrent) number of
episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization
for heart failure, development of end-stage kidney disease, kidney transplantation, and
mortality, counting all events from randomization until end of study.